Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PW Medtech GroupFRA:PWE +0.99%56 5-Year Yield-on-Cost % is 7.03 as of Jul. 29, 2026, which is 6% above its 10-year median of 6.64. GuruFocus rates FRA:PWE with a GF Score™ of 56/100 and a GF Value™ of €0.13 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 322 Medical Devices & Instruments companies, PW Medtech Group ranks better than 81.99% on this metric.
PW Medtech Group's yield on cost for the quarter that ended in Dec. 2025 was 7.03.
The historical rank and industry rank for PW Medtech Group's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:PWE'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 4.27 Med: 6.64 Max: 10.11
Current: 7.03
During the past 13 years, PW Medtech Group's highest Yield on Cost was 10.11. The lowest was 4.27. And the median was 6.64.
FRA:PWE's 5-Year Yield-on-Cost % is ranked better than 81.99% of 322
companies
in the Medical Devices & Instruments industry
Industry Median: 2.445
vs FRA:PWE: 7.03
PW Medtech Group (FRA:PWE) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
PW Medtech Group 5-Year Yield-on-Cost % Related Terms
FRA:PWE vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, PW Medtech Group's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PW Medtech Group 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PW Medtech Group's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where PW Medtech Group's 5-Year Yield-on-Cost % falls into.
PW Medtech Group 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
PW Medtech Group (FRA:PWE) has a 5-Year Yield-on-Cost % of 7.03 as of Jul. 29, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on PW Medtech Group and its competitors. This is near median its historical median of 6.64. Over the past decade, PW Medtech Group's 5-Year Yield-on-Cost % has ranged from 4.27 to 10.11. According to the industry distribution chart, PW Medtech Group ranks #58 out of 322 companies in the Medical Devices & Instruments industry, placing it in the top 18%.
Is PW Medtech Group's 5-Year Yield-on-Cost % too high?
PW Medtech Group's current 5-Year Yield-on-Cost % of 7.03 is near median its 10-year median of 6.64. Over the past 10 years, this metric has ranged from a low of 4.27 to a high of 10.11. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.45. PW Medtech Group's value of 7.03 is 187.5% above this industry median. Based on the distribution chart, PW Medtech Group ranks #58 out of 322 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, PW Medtech Group has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PW Medtech Group's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PW Medtech Group ranks #58 out of 322 companies for 5-Year Yield-on-Cost %. This places PW Medtech Group in the top 18% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.45. PW Medtech Group's value of 7.03 is 187.5% above this benchmark. Historically, PW Medtech Group's own 5-Year Yield-on-Cost % has ranged from 4.27 to 10.11 over the past decade. While the company's 10-year median is 6.64 vs. the industry median of 2.45, PW Medtech Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.45, based on 322 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PW Medtech Group's current 5-Year Yield-on-Cost % of 7.03 is 187.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on PW Medtech Group and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PW Medtech Group's current 5-Year Yield-on-Cost % is 7.03, which is near median its own 10-year median of 6.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PW Medtech Group stock overvalued right now?
Based on GuruFocus' analysis, PW Medtech Group (FRA:PWE) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.13, compared to a current price of €0.10 — trading 21.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 7.03, which is near median its 10-year median of 6.64 and 187.5% above the Medical Devices & Instruments industry median of 2.45. PW Medtech Group's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For PW Medtech Group (FRA:PWE), the current 5-Year Yield-on-Cost % is 7.03 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PW Medtech Group (FRA:PWE) Overvalued in 2026?
Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued.
The current stock price of €0.10 is trading 21.5% below its estimated GF Value™ of €0.13.
GuruFocus considers PW Medtech Group to be Modestly Undervalued.
Key valuation signals for FRA:PWE:
5-Year Yield-on-Cost %: 7.03 (near median its 10-year median of 6.64)
GF Value™: €0.13 vs. price of €0.10 (21.5% below fair value)
Industry Position: 187.5% above the Medical Devices & Instruments median (#58 of 322)
No single metric tells the full story. See the FRA:PWE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
56GF Score
Get the complete analysis for FRA:PWE
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PWE has been successfully added to your 
